Why sponsors choose Nucleus Network: A 3-year performance overview

From biotech startups to global pharma, early-phase sponsors continue to trust Nucleus Network to deliver fast, high-quality results. Our newly released 3-Year Snapshot offers a clear view of what that partnership looks like in action.

Between 2022 and 2024, Nucleus Network conducted 304 early-phase clinical trials across a wide range of therapeutic areas and sponsor geographies. Reflecting the scale, capability, and flexibility of our integrated global network.

Our newly released snapshot reflects this continued momentum. It highlights the scale of studies conducted across our sites in Australia and the United States, and the growing number of sponsors who rely on our unified model to accelerate early development.